Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
Translational Lung Cancer Research · 2023-07 · 12 (7) · 1506-1516
DOI: 10.21037/tlcr-23-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Lung Cancer Research, 2023-07. Verfasst von MinDong Sung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology and Critical Care, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republi…. Die Arbeit wurde bisher 24-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Not all non-small cell lung cancer (NSCLC) patients will benefit from immune checkpoint therapy and use of these medications carry serious autoimmune adverse effects. Therefore, biomarkers are needed to better identify patients who will benefit from its use. Here, the correlation of overall survival (OS) with baseline and early treatment period serum biomarker responses was evaluated in patients with NSCLC undergoing immunotherapy.
Methods
Patients diagnosed with NSCLC undergoing immunotherapy (n=597) at a tertiary academic medical center in South Korea were identified between January 2010 and November 2021. The neutrophil-lymphocyte ratio (NLR), C-reactive protein (CRP), and lactate dehydrogenase (LDH) levels in the survival and non-survival groups were examined at baseline and early treatment periods. Additionally, aberrant laboratory parameters at each period were used to stratify survival curves and examine their correlation with one-year OS.
Results
In the non-survival group, the NLR, CRP, and LDH levels at the early treatment period were higher than those at the baseline (P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonology and Critical Care, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Sung, M., Jang, W. S., Kim, H. R., Park, J. A., Lim, S. M., Kim, H. R., Cho, B. C., Park, Y. R., & Hong, M. H. (2023). Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy. Translational Lung Cancer Research, 12(7), 1506-1516. https://doi.org/10.21037/tlcr-23-7
Vancouver
Sung M, Jang WS, Kim HR, Park JA, Lim SM, Kim HR, et al. Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy. Translational Lung Cancer Research. 2023;12(7):1506-1516. doi:10.21037/tlcr-23-7
BibTeX
@article{Sung2023,
author = {Sung, MinDong and Jang, Won Seok and Kim, Hae Reong and Park, Ji Ae and Lim, Sun Min and Kim, Hye Ryun and Cho, Byoung Chul and Park, Yu Rang and Hong, Min Hee},
title = {Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy},
journal = {Translational Lung Cancer Research},
year = {2023},
volume = {12},
number = {7},
pages = {1506--1516},
doi = {10.21037/tlcr-23-7}
}
EUVIMED